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Abstract 
Adenosine triphosphate–binding cassette transporter A1 (ABCA1) plays a critical role in the for-
mation and metabolism of high-density lipoproteins (HDLs). Adenosine triphosphate–binding cas-
sette transporter A1 in the liver and small intestine, in particular, accounts for approximately 90% of 
plasma HDL cholesterol. Therefore, any alterations in the hepatic and intestinal expression of 
ABCA1 could have a large impact on HDL biogenesis. We tested the hypothesis that ABCA1 expres-
sion is regulated differentially by different types of fatty acids in the liver and small intestine. Human 
hepatoma HepG2 and human small intestine epithelial FHs 74 Int cells were used as an in vitro 
model. Cells were incubated with saturated and unsaturated fatty acids in the presence or absence 
of T0901317, a synthetic agonist of liver X receptor. Unsaturated fatty acids decreased ABCA1 protein 
levels at 100 μmol/L of concentration regardless of the agonist with a minimal effect on messenger 
RNA abundance. Incubation of HepG2 and FHs 74 Int cells with rottlerin, a protein kinase C δ (PKCδ) 
inhibitor, increased ABCA1 protein but did not abolish linoleic acid–induced decrease in ABCA1 
protein levels. Depletion of PKCδ using small interfering RNA showed decreased ABCA1 protein 
levels in control, palmitic acid–, and linoleic acid–treated cells, but the repressive effect of linoleic 
acid was sustained. In conclusion, our results indicate that unsaturated fatty acids regulate ABCA1 
expression in HepG2 and FHs 74 Int cells at the posttranscriptional level, and PKCδ is likely to be 
involved in maintaining ABCA1 protein levels. 
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Abbreviations: apoA-I, apolipoprotein A-I; ABCA1, adenosine triphosphate–binding cassette trans-
porter A1; CVD, cardiovascular disease; DMSO, dimethyl sulfoxide; FBS, fetal bovine serum; HDL, 
high-density lipoprotein; LDL, low-density lipoprotein; LXR, liver X receptor; mRNA, messenger 
RNA; PKCδ, protein kinase C δ; qPCR, quantitative real-time polymerase chain reaction; siRNA, 
small interfering RNA. 
 
1. Introduction 
 
Adenosine triphosphate (ATP)–binding cassette transporter A1 (ABCA1) is a membrane 
transporter that mediates the efflux of phospholipid and free cholesterol to lipid-free or 
lipid-poor apolipoprotein A I (apoA-I), the major protein constituent in high-density lipo-
protein (HDL) particles, contributing to HDL biogenesis.1–3 The significant role of ABCA1 
in HDL metabolism is underscored by the finding that mutations in ABCA1 gene lead to 
near absence of plasma HDL cholesterol concentrations in patients with Tangier disease 
and familial HDL deficiencies4 as well as in mice.5,6 In particular, deletion of ABCA1 in the 
liver and intestine decreased plasma HDL cholesterol concentrations by approximately 
80% and 30%, respectively, indicating that ABCA1 in these tissues are quantitatively most 
important for maintaining plasma HDL cholesterol levels.7,8 
Transcription of ABCA1 is under the control of liver X receptor (LXR), a major transcrip-
tion factor for genes important in cholesterol metabolism in response to cellular cholesterol 
levels.9 In addition, ABCA1 expression is also regulated by fatty acids. Human macro-
phages treated with linoleic acid (18:2) showed lower ABCA1 expression compared with 
those incubated with palmitic acid (16:0).10 Adenosine triphosphate–binding cassette trans-
porter A1 messenger RNA (mRNA) levels in HepG2 and RAW 264.7 macrophages were 
also decreased by unsaturated fatty acids, with a reduction in ABCA1 promoter activity.11 
Mutation or deletion of direct repeat 4, the LXR/retinoid X receptor heterodimer binding 
element, in the promoter of ABCA1 abolished the suppressive effects of unsaturated fatty 
acids on the gene expression, suggesting that the inhibition is probably mediated through 
mechanisms involving LXR/retinoid X receptor.12 Posttranscriptional regulation of ABCA1 
by unsaturated fatty acids in macrophages has also been demonstrated. Wang et al.13 and 
Wang and Oram14–16 found that unsaturated fatty acids increased ABCA1 protein degra-
dation in macrophages by activating phospholipase D2 and, subsequently, protein kinase 
C δ (PKCδ), which, in turn, phosphorylates ABCA1 serine residues for protein degrada-
tion. In Caco-2 cells, posttranscriptional regulation of ABCA1 expression by unsaturated 
fatty acids was also suggested with a modest fatty acid–induced suppression of the gene 
transcription.17 
Individuals with obesity and type 2 diabetes are at high risk of cardiovascular disease 
(CVD).18–25 Particularly, lowered plasma HDL cholesterol concentrations by approximately 
15% to 30% in type 2 diabetic individuals are associated with an increased risk of CVD.26,27 
The decreased plasma HDL cholesterol levels in diabetic subjects could contribute to their 
high CVD risk. High-density lipoprotein can deliver excess cholesterol from the periphery 
to the liver for ultimate excretion from the body. This process called “reverse cholesterol 
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transport” is believed to be a major atheroprotective property of HDL.28–30 Therefore, any 
disturbance in this process could facilitate cholesterol accumulation and foam cell formation 
in the arterial wall, a primary hallmark of atherosclerosis. High plasma free fatty acid con-
centrations are typically associated with obesity, insulin resistance, and type 2 diabetes31–35 
and are known to have a large impact on insulin resistance and diabetic dyslipidemia.36–46 
Therefore, the objective of this study was to evaluate the effect of various fatty acids on the 
expression of ABCA1 in the liver and intestine, which are primary sites for HDL formation, 
using HepG2, a human hepatoma cell line, and FHs 74 Int cells, a human small intestine 
epithelial cell line. To achieve the goal, we tested the hypothesis that ABCA1 expression is 
regulated differentially by different types of fatty acids in the liver and small intestine. FHs 
74 Int cell line has received very little attention to study metabolic events occurring in small 
intestine. In contrast to Caco-2 cell line that is most commonly used, FHs 74 Int cell line 
may have advantages over Caco-2 cells, as they are derived from fetal human small intes-
tinal epithelial cells, whereas Caco-2 cells are generated from large intestine. 
 
2. Methods and materials 
 
2.1. Cell culture and fatty acid preparation 
HepG2 cells and FHs 74 Int cells were purchased from ATCC (Manassas, Virginia, USA). 
The cells were maintained in minimal essential medium containing 10% fetal bovine serum 
(FBS), 100 U/mL penicillin, 100 μg/mL streptomycin, 1× vitamins, and 2 mmol/L L-gluta-
mine in a humidified chamber at 37°C with 5% CO2. For FHs 74 Int cells, 30 ng/mL epider-
mal growth factor and 10 μg/mL insulin were additionally supplemented to cell culture 
medium. All cell culture supplies were purchased from MediaTech (Manassas, Virginia, 
USA). 
Fatty acid and bovine serum albumin (BSA) complex (BSA to fatty acid molar ratio of 
2.5) was prepared, as previously described.47 Briefly, 2 mmol/L of fatty acid–poor and en-
dotoxin-free BSA (Calbiochem, EMD Chemicals, Gibbstown, New Jersey, USA) was pre-
pared in phosphate-buffered saline. Sodium salts of fatty acids (Nu-Chek-Prep, Inc., 
Elysian, Minnesota, USA) were dissolved in the BSA stock solution to a concentration of 5 
mmol/L. After purging with N2, the solution was sonicated in a water bath until it became 
clear to form the BSA/fatty acid complex (1:2.5 molar ratio of BSA to fatty acid). The com-
plex was sterilized through a Millex-GV 0.22 μmol/L filter unit (Millipore, Millerica, Mas-
sachusetts, USA) and diluted with cell medium to reach a final concentration of 100 
μmol/L. HepG2 cells were incubated with or without 10 μmol/L of T0901317 (Sigma-Al-
drich, St. Louis, Missouri, USA), an LXR agonist, in dimethyl sulfoxide (DMSO) for 18 
hours, after which cells were treated with BSA only (control) or 100 μmol/L of a fatty acid 
for 12 hours. For the experiments with rottlerin (Santa Cruz Biotechnology, Santa Cruz, 
California), a PKCδ inhibitor, cells were preincubated with 5 or 10 μmol/L rottlerin in 
DMSO for 2 hours and, subsequently, were incubated with BSA or 100 μmol/L fatty acids 
such as palmitic acid (16:0) and linoleic acid (18:2) for 12 hours. Control cells were incu-
bated with the same amount of DMSO for a vehicle control, in addition to BSA. Cells were 
cultured in a complete medium devoid of FBS when they were treated with fatty acid to 
eliminate any potential contamination of fatty acids present in FBS. 
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2.2. Small interfering RNA transfection 
To knock down PKCδ, HepG2 cells were transfected with Silencer Negative Control scram-
bled small interfering RNA (siRNA) (Ambion, Austin, Texas, USA) or siGENOME PKCδ 
siRNA (Dharmacon, Lafayette, Colorado, USA) using a transfection reagent DharmaFECT1 
(Dharmacon, Lafayette, Colorado, USA) according to the manufacturer’s protocol, as pre-
viously described.47 
 
2.3. Total RNA isolation and quantitative real-time polymerase chain reaction 
Total RNA was extracted from cells using TRIzol reagent (Invitrogen, Carlsbad, California, 
USA) following the manufacturer’s protocol. Reverse transcription for complementary 
DNA synthesis and quantitative real-time polymerase chain reaction (qPCR) analysis were 
performed, as previously described.48,49 Primers were designed according to GenBank da-
tabase using the Primer Express software (Applied Biosystems, Carlsbad, California, USA). 
The following primers were used for real-time polymerase chain reaction analysis: ABCA1, 
forward (5′-CGTTTCCGGGAAGTGTCCTA-3′), reverse (5′-GCTAGAGATGACAAGGAG 
GATGGA-3′); glyceraldehyde 3-phosphate dehydrogenase, forward (5′-GTGGTCTCCTCT 
GACTTCAACA-3′), reverse (5′-GTTGCTGTAGCCAAATTCGTTGT-3′). 
 
2.4. Western blot analysis 
Cell lysate was prepared, and Western blot analysis was performed, as previously de-
scribed.48,49 Rabbit anti-ABCA1 antibody was a generous gift from Dr. John Parks at Wake 
Forest University School of Medicine, and PKCδ antibody was purchased from Santa Cruz 
Biotechnology (Santa Cruz, California). β-Actin (Sigma-Aldrich, Missouri) was used as a 
loading control to normalize the data. 
 
2.5. Statistical analyses 
Analysis of variance and the Tukey pairwise comparison with Welch’s correction for unequal 
variance when appropriate were used to identify statistically significant differences of 
treatments, with P < .05 considered significant by GraphPad InStat 5 (LaJolla, California, 
USA). Data are expressed as mean ± SEM. 
 
3. Results 
 
HepG2 cells were treated with various fatty acids in the presence or absence of T0901317. 
In the absence of the LXR agonist, ABCA1 mRNA abundance was not significantly differ-
ent in all of fatty acid–treated cells compared with control (Fig. 1A). T0901317 markedly 
increased ABCA1 mRNA levels by approximately 7- to 25-fold. Saturated and monoun-
saturated fatty acids minimally altered ABCA1 mRNA, whereas significantly higher 
mRNA levels were observed in cells treated with polyunsaturated fatty acids, that is, 18:2, 
and eicosapentaenoic acid (20:5), than control in the presence of T0901317. However, 
ABCA1 protein (approximately 250 kd) was noticeably decreased by unsaturated fatty ac-
ids tested, that is, 18:1, 18:2, and 20:5, compared with the control and saturated fatty acid–
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treated cells, irrespective of the presence of T0901317 (Fig. 1B). In particular, polyunsatu-
rated fatty acids decreased ABCA1 protein levels to the greatest extent. Similar posttran-
scriptional regulation of ABCA1 by 18:2 was observed in FHs 74 Int cells (Fig. 2A and B). 
 
 
 
Figure 1. Unsaturated fatty acids inhibited ABCA1 expression at the posttranscriptional 
level in HepG2 cells. Cells were incubated with or without an LXR agonist T0901317 (10 
μmol/L) for 18 hours and, subsequently, with BSA only (control) or fatty acids (100 
μmol/L) complexed with BSA for 12 hours. A, Adenosine triphosphate–binding cassette 
transporter A1 mRNA abundance by qPCR. Values are expressed as means ± SEM; n = 6. 
Bars without a common letter are significantly different; P < .05. B, Adenosine triphosphate–
binding cassette transporter A1 protein by Western blot analysis with β-actin as a loading 
control. A representative blot of 2 separate experiments is shown. Densitometry analysis 
was conducted using β-actin for normalization, and ABCA1 protein expression levels rel-
ative to control without T0901317 treatment are shown as numbers below the gel image. 
Values of 2 lanes of the same treatment are averaged. 
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Figure 2. Unsaturated fatty acids inhibited ABCA1 expression at the posttranscriptional 
level in FHs 74 Int cells. Cells were without or with T0901317 (10 μmol/L) for 18 hours 
and, subsequently, with BSA only (control) or fatty acids (100 μmol/L) complexed with 
BSA for 12 hours. A, Adenosine triphosphate–binding cassette transporter A1 mRNA 
abundance by qPCR. Values are expressed as means ± SEM; n = 6. Bars without a common 
letter are significantly different; P < .05. There was no statistical significance detected be-
tween groups in the presence of T901317. B, Adenosine triphosphate–binding cassette 
transporter A1 protein of cells treated with fatty acids in the presence of T0901317 is vis-
ualized by Western blot analysis, with β-actin as a loading control. A representative blot 
of 2 separate experiments is shown. 
 
Degradation of ABCA1 is an important regulatory mechanism for its activity.50,51 Post-
transcriptional regulation of ABCA1 by unsaturated fatty acids is suggested to result from 
destabilization of ABCA1 protein through its phosphorylation by PKCδ in macrophages.16 
To evaluate if the same mode of action exists in HepG2 and FHs 74 Int cells, the cells were 
incubated with 16:0 or 18:2 in the presence of 5 or 10 μmol/L of rottlerin, a PKCδ inhibitor. 
Although rottlerin tended to increase ABCA1 protein in most treatments, it did not abolish 
the repressive effect of 18:2 on ABCA1 protein in HepG2 cells (Fig. 3A) and FHs 74 Int cells 
(Fig. 3B). To further verify the involvement of PKCδ in the degradation of ABCA1 protein 
by unsaturated fatty acids, HepG2 cells were transfected with control scrambled or PKCδ 
siRNA to knockdown PKCδ; and, subsequently, the cells were incubated with 16:0 and 
18:2. Depletion of PKCδ by approximately 70% to 90% by siRNA was not able to abolish 
the repressive effect of 18:2 on ABCA1 protein (Fig. 4). Interestingly, knockdown of PKCδ 
decreased ABCA1 protein in all treatments, suggesting that PKCδ might play a role in 
maintaining ABCA1 protein levels in the cell line. 
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Figure 3. Rottlerin increased ABCA1 protein but could not reverse unsaturated fatty acid–
induced down-regulation of ABCA1 protein expression in HepG2 and FHs 74 Int cells. 
HepG2 (A) and FHs 74 Int (B) cells were preincubated with rottlerin (5 and 10 μmol/L) for 
2 hours, after which they were treated with BSA only (control), 16:0 or 18:2 (100 μmol/L) 
for 12 hours. Adenosine triphosphate–binding cassette transporter A1 protein expression 
was measured by Western blot analysis using β-actin as a loading control. A representa-
tive blot of 2 separate experiments is shown, and relative ABCA1 protein levels to control 
with no rottlerin treatment based on densitometry analysis are listed. 
 
 
 
Figure 4. Depletion of PKCδ failed to abolish decreased ABCA1 protein levels by unsatu-
rated fatty acids in HepG2 cells. Cells were transfected with 100 nmol/L of scrambled 
control or PKCδ siRNA for 24 hours and subsequently incubated with BSA only (control), 
16:0 or 18:2 (100 μmol/L) for 24 hours. Adenosine triphosphate–binding cassette trans-
porter A1 and PKCδ protein levels were determined by Western blot analysis using β-
actin as a loading control. A representative blot of 2 separate experiments is shown, and 
relative ABCA1 protein levels to scrambled control based on densitometry analysis are 
listed. Sc indicates scrambled control. 
 
4. Discussion 
 
Of the various complications associated with type 2 diabetes, CVD is the leading cause of 
morbidity and mortality in diabetic subjects with 2- to 8-fold higher risk than the nondi-
abetic population.52–54 As increased plasma free fatty acid concentrations and influx into 
tissues have been suggested to play a role in diabetic dyslipidemia31–33, 36–38 and ABCA1 in 
the liver and intestine is the major factor to maintain plasma HDL cholesterol levels,7,8 our 
current study was undertaken to investigate the effect of fatty acids on the hepatic and 
intestinal ABCA1 expression. We found that unsaturated fatty acids, polyunsaturated fatty 
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acids in particular, repressed ABCA1 expression in HepG2 and FHs 74 Int cells at the post-
transcriptional level and that PKCδ could play an important role in maintaining ABCA1 
protein levels. 
Adenosine triphosphate–binding cassette transporter A1 facilitates the efflux of phos-
pholipid and free cholesterol to lipid-free or lipid-poor apoA-I, which is the critical step 
for HDL biogenesis.2,3 In vitro interaction of apoA-I with ABCA1 produces heterogeneous-
sized, pre-β HDL subpopulations, which have a different metabolic fate depending on the 
degree of lipidation, with less lipidated HDL being rapidly removed by kidney.55,56 Tissue 
site of ABCA1 expression is also important for the production of HDL, as dysfunctional 
ABCA1 in the liver and intestine led to decreased plasma HDL cholesterol concentrations 
by approximately 80% and 30%, respectively.7,8 The studies emphasize a pivotal role of 
ABCA1 in HDL biogenesis by lipidating newly secreted apoA-I in the liver and intestine, 
which are exclusive sites of apoA-I secretion. Accordingly, lack of interaction of apoA-I 
with ABCA1 in the liver and intestine due to diminished ABCA1 expression could possibly 
lower the production of nascent HDL, consequently reducing plasma HDL cholesterol lev-
els. In the present study, ABCA1 protein levels were significantly lowered by unsaturated 
fatty acids but not by saturated fatty acids without reducing its mRNA abundance in 
HepG2 and FHs 74 Int cells. The posttranscriptional inhibition of ABCA1 expression has 
also been shown in other cells.11,13,14,17 Considering the critical role of hepatic and intestinal 
ABCA1 in HDL biogenesis, the diminished ABCA1 expression by unsaturated fatty acids 
could have a negative impact on plasma HDL cholesterol concentrations. 
Although much attention has been given to the changes in plasma total and low-density 
lipoprotein (LDL) cholesterol concentrations in response to dietary fatty acids, studies 
have shown that dietary fatty acids can alter plasma HDL cholesterol levels. Isoenergetic 
substitution of n-3 polyunsaturated fatty acids for saturated fatty acids decreased plasma 
concentrations of total cholesterol, LDL cholesterol, and HDL cholesterol in nonhuman 
primates57 and humans.58 African green monkeys fed atherogenic diets containing polyun-
saturated fatty acids had significantly decreased plasma concentrations of total cholesterol, 
HDL cholesterol, and apoA-I compared with saturated and monounsaturated fatty acid–
fed animals.59 In addition, a recent study in humans reported that plasma HDL cholesterol 
concentrations were lower when subjects were on a polyunsaturated fatty acid–rich diet 
compared with a saturated fatty acid–rich diet.60 Therefore, studies exist to support an 
HDL cholesterol–lowering effect of unsaturated fatty acid and polyunsaturated fatty acids 
in particular, relative to saturated fatty acids. We found that all unsaturated fatty acids 
decreased ABCA1 protein levels in HepG2 cells but that polyunsaturated fatty acids, such 
as 18:2 and 20:5, induced the greatest reduction. Our data suggest that the decreased 
plasma HDL cholesterol concentrations by unsaturated fatty acids compared with satu-
rated fatty acids could be, at least in part, attributed to diminished hepatic and intestinal 
ABCA1 expression, lowering nascent HDL formation. 
Turnover of ABCA1 protein is rapid with a half-life of less than 1 hour in murine mac-
rophage–like cells and differentiated THP-1 cells,51,61 suggesting that posttranscriptional 
regulation could be an important determinant for its function. Unsaturated fatty acids, but 
not saturated fatty acids, were shown to increase ABCA1 protein degradation in macro-
phages and baby hamster kidney cells by activating phospholipase D2 and, subsequently, 
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PKCδ, which resulted in the serine phosphorylation and destabilization of ABCA1.15,16 
However, we found that neither rottlerin nor depletion of PKCδ by siRNA abolished the 
repressive effect of 18:2 on ABCA1 protein levels in HepG2 and FHs 74 Int cells. Instead, 
rottlerin treatment tended to increase the transporter protein, whereas PKCδ knockdown 
lowered protein levels independent of types of fatty acids. Our results indicate that PKCδ 
is not involved in facilitating ABCA1 protein degradation by unsaturated fatty acids in 
HepG2 and FHs 74 Int cells and that it is likely to play a role in maintaining ABCA1 protein 
expression. The reasons for the contradictory observations between our results and previ-
ously reported data are not clear. However, as we found the similar response in RAW 264.7 
macrophages (manuscript in submission), we do not think the contradiction is because of 
different cell types used in the 2 studies. More investigation is necessary to explain the 
difference. 
Although rottlerin has been widely used as a selective PKCδ inhibitor, there is a recent 
debate on its selectivity for PKCδ, as it inhibits other kinases.62 Increased ABCA1 expres-
sion by rottlerin but decreased expression by PKCδ siRNA shown in our study favor that 
rottlerin is not a PKCδ-specific inhibitor. Phosphorylation of ABCA1 can alter its protein 
degradation or activity depending on sites of phosphorylation. Phosphorylation in the 
PEST sequence (proline, glutamic acid, serine, and threonine) of ABCA1 is shown to in-
crease the protein degradation by calpain,63,64 whereas ABCA1 protein levels are positively 
correlated to its phosphorylation in THP-1 cells.50 Given that rottlerin treatment enhanced 
ABCA1 proteins, we speculate that kinases susceptible to the inhibition by rottlerin could 
be present to lower ABCA1 protein in HepG2 and FHs 74 Int cells. Identification of the 
kinases and phosphorylation sites in ABCA1 is important to increase ABCA1 expression 
and, consequently, plasma HDL cholesterol concentrations. 
In summary, the present study demonstrated that unsaturated fatty acids lower ABCA1 
expression in HepG2 and FHs 74 Int cells. The inhibition by unsaturated fatty acids could 
have a large impact on HDL formation, lowering plasma HDL cholesterol concentrations. 
As plasma HDL cholesterol levels are inversely related to the risk of CVD, one could argue 
that the potential unfavorable effect of unsaturated fatty acid on ABCA1 contradicts a well-
known atheroprotective role of unsaturated fatty acids, polyunsaturated fatty acids in par-
ticular, compared with saturated fatty acids. Atheroprotection of polyunsaturated fatty ac-
ids, however, is attributable to their effects on very low-density lipoprotein, LDL, and 
triglyceride metabolism, anti-inflammation, and antithrombosis.57,65–67 These benefits could 
override the inhibition of hepatic and intestinal ABCA1 expression by polyunsaturated 
fatty acids in protecting against atherosclerosis. The repressive effect of unsaturated fatty 
acids on ABCA1 expression has a particular health implication in obese and type 2 diabetic 
subjects, whose plasma free fatty acids are commonly elevated. Increased fatty acid influx into 
tissues consequent to high plasma fatty acid levels is known to perturb various metabolic 
pathways related to insulin resistance and diabetic dyslipidemia. Proper dietary interven-
tions for the pathologic conditions require our better understanding of the modulation of 
ABCA1 expression by fatty acids. In vivo study warrants verification of our in vitro find-
ings to develop dietary strategy to achieve relative abundance of each type of fatty acids 
in the diet to maintain optimal health. 
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